Content Click below to navigate through the document Company overview Financial review Conclusions Investor presentation October 28, 2025 Novartis Q3 Results | October 28, 2025 1 Content Click below to navigate through the document Appendix References Q3 2025 Results Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be i ...

Market Overview - European stocks are expected to open flat to higher, with the U.K.'s FTSE index slightly up, Germany's DAX and France's CAC 40 down by 0.2%, and Italy's FTSE MIB just below the flatline [1] Federal Reserve Meeting - The U.S. Federal Reserve's two-day meeting begins on Tuesday, with a 96% chance of a 25 basis-point rate cut anticipated by the market [2] - Traders are looking for signals from Fed Chair Jerome Powell regarding another potential rate cut at the final meeting of the year in December due to concerns about a weakening labor market [2] Economic Data and Geopolitical Concerns - The Fed is facing an economic data blackout due to the ongoing U.S. government shutdown, with limited recent data available, including last week's inflation report [3] - Geopolitical issues, particularly the U.S.-China trade dispute, are also significant for investors, with a meeting scheduled between President Trump and President Xi Jinping in South Korea to address trade tensions [3] Trade Negotiations - Both the U.S. and China appear to be in a conciliatory mood, having agreed on a framework for a potential trade deal that includes topics such as rare earths export restrictions, soybean purchases, and TikTok [4] - President Trump expressed optimism about reaching a deal with President Xi during their upcoming meeting at the APEC Summit [4] Earnings Reports - Key earnings reports in Europe on Tuesday include Novartis, BNP Paribas, Capgemini, Air Liquide, Iberdrola, ASM International, and Logitech [5] - HSBC, Europe's largest lender, reported third-quarter profits that exceeded expectations [5]

Core Points - Novartis announced the expiration of its tender offer to acquire Tourmaline Bio, Inc. at a price of $48.00 per share, which ended on October 27, 2025 [1][2] - Approximately 24,030,382 shares were validly tendered, representing about 92.94% of the outstanding shares prior to the expiration [2] Company Information - Novartis is an innovative medicines company focused on improving and extending lives through its products, reaching over 300 million people globally [5]

Novartis profit rose last quarter, boosted by new cancer drugs https://t.co/XDZFh4UkmE ...

行情回顾及主要观点： 上周A股市场整体呈现上涨趋势，主要指数普遍反弹：沪深300涨2.9%，中证500涨3.5%，中证1000涨 3.3%，创业板50涨9.5%，科创50涨7.3%。交易面，A股市场上周日均成交额在1.8万亿元左右，市场交 易面有所缩量。市场热点呈现快速轮动特征，行业板块从算力硬件、煤炭向光模块CPO、航空航天、油 气等转换。当前市场风格以结构性机会为主，中长期建议结合十五五规划把握政策支持与产业共振的投 资方向，全会提出要 "培育壮大新兴产业和未来产业"，重点关注创业板相关投资机会。 创业板为主要"三创（创新、创造、创意）四新（新技术、新产业、新业态、新模式）"的成长型创新创 业企业提供直接融资平台。权重行业方面，创业板50指数聚焦信息技术+新能源+金融科技+医药四大新 质生产力赛道，科技成长属性纯粹。 10-24 图：创业板50指数四大赛道 创业板50指数：追"光"识"新"更掘"金"。横向对比来看，创业板50指数的光模块含量、新能源含量以及 金融科技含量优于创业板指以及主流宽基指数。 图3：创业板50指数高含"光"量、含"新"量、含"金"量 | 指数代码 | 指数名称 光模块 | 新能源 ...

Core Insights - Swiss drugmaker Novartis reported a 6% increase in operating income, driven by the growth of its new drugs, which compensated for stagnant revenue from the established heart drug Entresto [1] Company Performance - Novartis experienced a 6% gain in operating income, indicating a positive trend in its financial performance [1] - The growth of new drugs played a crucial role in offsetting the lack of revenue growth from Entresto, highlighting the importance of innovation in the company's portfolio [1] Industry Context - The performance of Novartis reflects broader trends in the pharmaceutical industry, where new drug development is essential for maintaining revenue streams amid competition and market saturation [1]

近期上市公司陆续披露三季报，科创板企业展现出优异的业绩。海光信息前三季度实现总营业收入 94.90亿元，同比增长54.65%；归母净利润19.61亿元，同比增长28.56%。公司称，这一增长主要归因于 公司与整机厂商、生态伙伴在重点行业和重点领域的深化合作，以及加速客户端导入，推动高端处理器 产品的市场版图扩展。寒武纪前三季度实现营业收入46.07亿元，同比大幅增长2386.38%；归母净利润 16.05亿元，同比扭亏为盈。据公司介绍，业绩增长主要系在报告期内持续拓展市场，以及公司积极助 力人工智能应用落地。截至三季度末，公司预付款项、存货规模分别达到6.90亿元、37.29亿元，其中存 货较二季度末环比增长近4成，再创历史新高。（以上个股仅作示例，不作为投资建议） 解读： 科创板政策及行业动态一览： 科创板政策与行业动向： 随着三季报陆续披露，多家科创板企业业绩亮眼。AI算力芯片、光通信等新兴产业的科创板企业延续 了上半年业绩的良好增势，量子计算、新能源领域的多家企业则大方披露前沿技术的商业化进展，凸显 了科创板在培育战略新兴及未来产业、形成新质生产力方面的引领作用。 当前逆全球化加剧，自主可控需求迫切。科 ...

Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease1INShore is the first global phase III study of a targeted therapy in this chronic kidney disease commonly diagnosed in early childhood Basel, 28 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today st ...

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority brands including Kisqali (+68% cc), Kesimpta (+44% cc), Pluvicto (+45% cc) and Scemblix (+95% cc)Core operating income margin1 was stable (cc) at 39.3% despite increasing generic impact Q3 operating income grew +27% (cc, +24% USD); net income rose +25% (cc, +23% USD)Q3 core EPS1 grew +10% (cc, +9% USD) to USD 2.25 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the Phase III INShore study of Gazyva® (obinutuzumab) in children and young adults (aged 2-25 years) with idiopathic nephrotic syndrome (INS). The study met its primary endpoint, with more people achieving sustained complete remission at one year (week 52) with Gazyva compared with mycophenolate mofet. ...